308 related articles for article (PubMed ID: 25557115)
1. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.
Guin S; Theodorescu D
Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115
[TBL] [Abstract][Full Text] [Related]
2. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
3. RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.
Yan C; Theodorescu D
Pharmacol Rev; 2018 Jan; 70(1):1-11. PubMed ID: 29196555
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Ral GTPases Using a Stapled Peptide Approach.
Thomas JC; Cooper JM; Clayton NS; Wang C; White MA; Abell C; Owen D; Mott HR
J Biol Chem; 2016 Aug; 291(35):18310-25. PubMed ID: 27334922
[TBL] [Abstract][Full Text] [Related]
5. Drugging the Ral GTPase.
Yan C; Jones DN; Theodorescu D
Small GTPases; 2015; 6(3):157-9. PubMed ID: 26280620
[TBL] [Abstract][Full Text] [Related]
6. Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
Pomeroy EJ; Eckfeldt CE
Small GTPases; 2020 Jan; 11(1):39-44. PubMed ID: 28682649
[TBL] [Abstract][Full Text] [Related]
7. Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.
El-Chaar NN; Piccolo SR; Boucher KM; Cohen AL; Chang JT; Moos PJ; Bild AH
Mol Oncol; 2014 Oct; 8(7):1339-54. PubMed ID: 24908424
[TBL] [Abstract][Full Text] [Related]
8. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
9. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
10. Across the universe of K-RAS mutations in non-small-cell-lung cancer.
Piva S; Ganzinelli M; Garassino MC; Caiola E; Farina G; Broggini M; Marabese M
Curr Pharm Des; 2014; 20(24):3933-43. PubMed ID: 24138715
[TBL] [Abstract][Full Text] [Related]
11. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.
Peschard P; McCarthy A; Leblanc-Dominguez V; Yeo M; Guichard S; Stamp G; Marshall CJ
Curr Biol; 2012 Nov; 22(21):2063-8. PubMed ID: 23063435
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
[TBL] [Abstract][Full Text] [Related]
13. KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Lee JS; Shim HS; Chang YS
Lung Cancer; 2014 Aug; 85(2):299-305. PubMed ID: 24863005
[TBL] [Abstract][Full Text] [Related]
14. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M
Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110
[TBL] [Abstract][Full Text] [Related]
15. [Targeting the RAS signalling pathway in cancer].
Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
[TBL] [Abstract][Full Text] [Related]
16. Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.
Gentry LR; Nishimura A; Cox AD; Martin TD; Tsygankov D; Nishida M; Elston TC; Der CJ
J Biol Chem; 2015 Sep; 290(37):22851-61. PubMed ID: 26216878
[TBL] [Abstract][Full Text] [Related]
17. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of small molecules that target the GTPase Ral.
Yan C; Liu D; Li L; Wempe MF; Guin S; Khanna M; Meier J; Hoffman B; Owens C; Wysoczynski CL; Nitz MD; Knabe WE; Ahmed M; Brautigan DL; Paschal BM; Schwartz MA; Jones DN; Ross D; Meroueh SO; Theodorescu D
Nature; 2014 Nov; 515(7527):443-7. PubMed ID: 25219851
[TBL] [Abstract][Full Text] [Related]
19. [Targeting KRAS pathway in NSCLC therapy].
Le Moulec S; Loriot Y; Soria JC
Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
[TBL] [Abstract][Full Text] [Related]
20. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
Vasan N; Boyer JL; Herbst RS
Clin Cancer Res; 2014 Aug; 20(15):3921-30. PubMed ID: 24893629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
